US2012027815A1PendingUtilityA1

Use of plasma membrane calcium atpase (pmca) inhibitors to inhibit sperm mobility

Assignee: NEYSES LUDWIGPriority: Jul 3, 2003Filed: Aug 2, 2011Published: Feb 2, 2012
Est. expiryJul 3, 2023(expired)· nominal 20-yr term from priority
Inventors:Ludwig Neyses
A61P 43/00Y10S435/806A61K 31/343A61P 15/16A61P 15/00A61P 15/18A61K 31/352
22
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of plasma membrane calcium ATPase (PMCA) inhibitors for inhibiting sperm mobility to achieve a contraceptive effect. The invention further relates to contraceptive agents comprising one or more PMCA inhibitors.

Claims

exact text as granted — not AI-modified
1 . A method of achieving contraception comprising:
 administering a composition comprising an inhibitor that specifically binds to a plasma membrane calcium ATPase 4 (PMCA4) isoform in sperm to effectively suppress sperm mobility.   
     
     
         2 . The method according to  claim 1 , wherein the composition comprises an intracellular-acting inhibitor or an extracellular-acting inhibitor or a combination thereof. 
     
     
         3 . The method according to  claim 2 , wherein the composition comprises one or more inhibitors selected from the group consisting of a 5-carboxyeosindiacetate succinimidyl ester, a 6-carboxyeosindiacetate succinimidyl ester, an eosin, a fluorescein, Caloxin-2A1 and spermin. 
     
     
         4 . The method according to  claim 1 , wherein administering the composition is carried out orally, parenterally or as a coating on a mechanical contraceptive, or in the form of a cream, a gel, or an oil. 
     
     
         5 . The method according to  claim 1 , wherein administering the composition is performed as a single contraceptive dose or as a repeated contraceptive dose. 
     
     
         6 . The method according to  claim 1 , wherein the composition is administered to a mammal. 
     
     
         7 . The method according to  claim 6 , wherein the mammal is a human being. 
     
     
         8 . A contraceptive formulation comprising the composition of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         9 . The contraceptive formulation according to  claim 8 , wherein the contraceptive composition is administered with a conventional contraceptive. 
     
     
         10 . The contraceptive formulation according to  claim 9 , wherein the conventional contraceptive is a condom, a mechanical contraceptive device, or a spermicidal preparation.

Join the waitlist — get patent alerts

Track US2012027815A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.